Mission Bio, a leader in single-cell multiomics for precision medicine, has announced a collaboration with Dr. C. Ola Landgren, MD, PhD, director of a renowned myeloma research laboratory. Dr. Landgren, along with Dr. David Coffey and Dr. Benjamin Diamond from the University of Miami’s Sylvester Comprehensive Cancer Center, will use Mission Bio’s Tapestri Single-cell DNA Multiple Myeloma Panel to create clinical data sets. This collaboration aims to examine Multiple Myeloma (MM) with unprecedented clonal detail, potentially uncovering insights that could improve outcomes for MM patients.
Multiple Myeloma (MM) is a challenging and incurable blood cancer affecting approximately 230,000 people worldwide. Relapse is a major issue, with up to 50% of patients experiencing relapse within the first year of treatment, and only 20% surviving for five years with current therapies.
The key to controlling relapse in MM lies in understanding resistant clones—cells that develop mutations enabling them to evade treatment. However, current tools do not adequately profile the disease from the initial emergence of these clones to full-blown myeloma. In collaboration with the University of Miami, the goal is to predict which patients are at higher risk of relapse and to guide treatment decisions upon relapse. Additionally, the project will explore whether blood samples could replace bone marrow samples, offering a less invasive and more accessible option for patient testing.
Dr. C. Ola Landgren, MD, PhD, said, “Multiple Myeloma is a genetically complex disease that remains difficult to understand using existing methods, particularly when it comes to predicting relapse and guiding treatment. Our goal is to use Tapestri to gain deeper insights into MM disease heterogeneity, enabling faster detection and treatment of relapse. We aim to demonstrate the clinical feasibility of the Multiple Myeloma assay and advance patient outcomes.”
Brian Kim, CEO of Mission Bio, stated, “Our partners are pushing the boundaries of single-cell DNA and multiomic analysis, and Dr. Landgren’s work promises to reveal critical insights that will help predict relapse and inform more personalized treatments for MM patients.”
For more information on the Tapestri Single-cell DNA Multiple Myeloma Panel, visit missionbio.com/products/panels/multiple-myeloma/.
About Mission Bio
Mission Bio is a leading life science company specializing in single-cell DNA and multiomics analysis. Its Tapestri Platform offers unmatched precision for complex research in cancer, pharmaceuticals, and gene therapies. Unlike traditional methods, Tapestri provides unparalleled granularity, enabling tailored treatment strategies. Researchers worldwide rely on Tapestri to identify rare cell populations, understand therapeutic resistance, and support the development of next-generation medical treatments. Founded in 2014, Mission Bio has received investment from Mayfield Fund, Novo Growth, Cota Capital, and Agilent Technologies, and continues to set the standard in personalized medicine and targeted therapies.
